专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016010662A9 QUINOXALINE COMPOUNDS, METHOD FOR PREPARING THE SAME AND USE THEREOF 审中-公开
标题翻译：喹喔啉化合物，其制备方法及其用途
公开(公告)号：WO2016010662A9
公开(公告)日：2016-08-25
申请号：PCT/US2015035822
申请日：2015-06-15
申请人： DEV CT BIOTECHNOLOGY , DCB-USA LLC
发明人： LIN NAN-HORNG , LIAO CHU-BIN , PENG SHAO-ZHENG , YEN SHIH-CHIEH , KUO MANN-YAN
IPC分类号： C07D239/72
CPC分类号： C07D241/44 , C07D401/12
摘要： A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR8 or O; R1, R2, R3, R4, R5, R6 and R7 are defined herein. Compounds of formula (I) are useful for inhibition of protein kinases. Methods of using compounds of formula (I), stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed
摘要翻译：用于治疗具有式（I）结构的蛋白激酶相关疾病或病症的化合物，其中L是NR 8或O; R1，R2，R3，R4，R5，R6和R7如本文所定义。式（I）化合物可用于抑制蛋白激酶。公开了使用式（I）化合物，其立体异构体，互变异构体和药学上可接受的盐用于体外，原位和体内诊断，预防或治疗哺乳动物细胞中的此类病症或相关病理学病症的方法

2. 发明公开

EP3169670A4 QUINOXALINE COMPOUNDS, METHOD FOR PREPARING THE SAME AND USE THEREOF 有权转让
标题翻译： CHINOXALINVERBINDUNGEN，VERFAHREN ZUR HERSTELLUNG DAVON UND VERWENDUNG DAVON
公开(公告)号：EP3169670A4
公开(公告)日：2017-05-24
申请号：EP15822821
申请日：2015-06-15
申请人： DEV CT BIOTECHNOLOGY , DCB-USA LLC
发明人： LIN NAN-HORNG , LIAO CHU-BIN , PENG SHAO-ZHENG , YEN SHIH-CHIEH , KUO MANN-YAN
IPC分类号： C07D241/44 , A61K31/498 , A61P35/00 , C07D401/12
CPC分类号： C07D241/44 , C07D401/12
摘要： wherein L is NR8 or O; R1, R2, R3, R4, R5, R6 and R7 are defined herein. Compounds of formula (I) are useful for inhibition of protein kinases. Methods of using compounds of formula (I), stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed
摘要翻译：用于治疗具有式（I）结构的蛋白激酶相关疾病或病症的化合物，其中L是NR 8或O; R1，R2，R3，R4，R5，R6和R7如本文所定义。式（I）化合物可用于抑制蛋白激酶。公开了使用式（I）化合物，其立体异构体，互变异构体和药学上可接受的盐用于体外，原位和体内诊断，预防或治疗哺乳动物细胞中的此类病症或相关病理学病症的方法

3. 发明专利

AU2018397483A1 Heterocycle compounds as Tyro3, Axl and Mertk (TAM) family of receptor tyrosine kinase inhibitors 未知
公开(公告)号：AU2018397483A1
公开(公告)日：2020-08-13
申请号：AU2018397483
申请日：2018-12-26
申请人： DEV CT BIOTECHNOLOGY
发明人： YEN SHIH-CHIEH , LIAO CHU-BIN , WANG HUI-CHEN , CHEN PO-TING , PAN YU-CHIH , LI TSUNG-HUI , CHEN BO-RONG , CHIOU SHIAN-YI
IPC分类号： C07D487/00 , A61K31/519
摘要： Disclosed are compounds of formula (I) below and tautomers, stereoisomers, isotopologues, or pharmaceutically acceptable salts thereof: in which each of variables R

4. 发明专利

AU2015290176A1 Quinoxaline compounds, method for preparing the same and use thereof 未知
公开(公告)号：AU2015290176A1
公开(公告)日：2017-02-16
申请号：AU2015290176
申请日：2015-06-15
申请人： DEV CT BIOTECHNOLOGY , DCB-USA LLC
发明人： LIN NAN-HORNG , LIAO CHU-BIN , PENG SHAO-ZHENG , YEN SHIH-CHIEH , KUO MANN-YAN
IPC分类号： C07D239/72
摘要： A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR

5. 发明专利

AU2015290176B2 Quinoxaline compounds, method for preparing the same and use thereof 未知
公开(公告)号：AU2015290176B2
公开(公告)日：2019-10-31
申请号：AU2015290176
申请日：2015-06-15
申请人： DCB USA LLC , DEV CT BIOTECHNOLOGY
发明人： LIN NAN-HORNG , LIAO CHU-BIN , PENG SHAO-ZHENG , YEN SHIH-CHIEH , KUO MANN-YAN
IPC分类号： C07D239/72
摘要： A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR

6. 发明专利

CA3088059A1 ANTIBODY PROTAC CONJUGATES 未知
公开(公告)号：CA3088059A1
公开(公告)日：2019-07-18
申请号：CA3088059
申请日：2019-01-09
申请人： DEV CT BIOTECHNOLOGY
发明人： CHUANG SHIH-HSIEN , LIAO CHU-BIN , SUN WEI-TING , LIANG CHEN-HSIEN , LIN WUN-HUEI , LAI CHUN-LIANG , LIN HER-SHENG
IPC分类号： A61K47/68 , A61P35/00 , C07K16/30
摘要： An immunoconjugate having the Formula Ab-[L1-(A-L2-B)m]n, wherein: (a) Ab is an antibody or a binding fragment thereof; (b) L1 and L2 are each independently a linker, wherein L1 and L2 are the same or different and wherein L1 links to L2; (c) A is a target-protein ligand/binder; (d) B is a ubiquitin ligase ligand/binder, and (e) n and m are independently integers from 1 to 8. The target protein includes kinase, G protein-coupled receptors, transcription factor, phosphatases, and RAS superfamily members.

7. 发明专利

CA3151821A1 HETEROCYCLIC PYRAZOLE DERIVATIVES AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS 未知
公开(公告)号：CA3151821A1
公开(公告)日：2021-03-04
申请号：CA3151821
申请日：2020-08-22
申请人： DEV CT BIOTECHNOLOGY
发明人： PENG SHAO-ZHENG , LIAO CHU-BIN , HUANG HUNG-JYUN , CHO YUAN-TING , CHANG YI-MEI , PAN YU-CHIH
IPC分类号： C07D471/04 , A61K31/437 , A61K31/444
摘要： A compound, which can act as inhibitors of protein kinases, especially Class III RTKs such as FLT3, PDGFRa, c-KIT and/or CSF-1R kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a binder of a Proteolysis-Targeting Chimera (PROTAC) thereof. The compound can be used in the treatments of diseases or conditions mediated by FLT3, PDGFR, c-KIT, and/or CSF-1R kinases, or mediated by a mutant kinase of FLT3, PDGFR, c-KIT, and/or CSF-1R kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.

8. 发明专利

AU2019206507A1 Antibody protac conjugates 未知
公开(公告)号：AU2019206507A1
公开(公告)日：2020-08-27
申请号：AU2019206507
申请日：2019-01-09
申请人： DEV CT BIOTECHNOLOGY
发明人： CHUANG SHIH-HSIEN , LIAO CHU-BIN , SUN WEI-TING , LIANG CHEN-HSIEN , LIN WUN-HUEI , LAI CHUN-LIANG , LIN HER-SHENG
IPC分类号： C07K16/30 , A61K47/68 , A61P35/00
摘要： An immunoconjugate having the Formula Ab-[L

9. 发明专利

SG11202005983TA HETEROCYCLE COMPOUNDS AS TYRO3, AXL AND MERTK (TAM) FAMILY OF RECEPTOR TYROSINE KINASE INHIBITORS 未知
公开(公告)号：SG11202005983TA
公开(公告)日：2020-07-29
申请号：SG11202005983T
申请日：2018-12-26
申请人： DEV CT BIOTECHNOLOGY
发明人： YEN SHIH-CHIEH , LIAO CHU-BIN , WANG HUI-CHEN , CHEN PO-TING , PAN YU-CHIH , LI TSUNG-HUI , CHEN BO-RONG , CHIOU SHIAN-YI
IPC分类号： A61K31/519 , C07D487/00
摘要： in which each of variables R1, ring A, L, W, V, and G is defined herein. Also disclosed are a method for treating disease or disorder mediated by Tyro3, Axl, and/or Mer kinase with a compound of formula (I) or a tautomer, stereoisomer, isotopologue, or salt thereof and a pharmaceutical composition containing same.

10. 发明专利

SG11201903091VA QUINOXALINE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS 未知
公开(公告)号：SG11201903091VA
公开(公告)日：2019-05-30
申请号：SG11201903091V
申请日：2017-10-09
申请人： DEV CT BIOTECHNOLOGY
发明人： PENG SHAO-ZHENG , LIAO CHU-BIN , CHEN HUNG-KAI , HO CHEN-HSUAN , HUANG HUNG-JYUN , CHIOU SHIAN-YI
IPC分类号： C07D241/40 , C07D241/44 , C07D401/12
摘要： INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 011111111 011100111111110111110111101111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/071348 Al 19 April 2018 (19.04.2018) WIP0 1 PCT (51) International Patent Classification: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, C07D 241/40 (2006.01) C07D 401/12 (2006.01) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, C07D 241/44 (2006.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (21) International Application Number: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, PCT/US2017/055809 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (22) International Filing Date: 09 October 2017 (09.10.2017) Published: (25) Filing Language: — English with international search report (Art. 21(3)) (26) Publication Language: English (30) Priority Data: 62/406,328 10 October 2016 (10.10.2016) US (71) Applicants: DEVELOPMENT CENTER FOR BIOTECHNOLOGY; No. 101, Lane 169, Kangning St , New Taipei City, 221 (TW). DCB-USA LLC [US/US]; 1007 N. Orange Street, Wilmington, DE 19801 (US). (72) Inventors: PENG, Shao-Zheng; c/o DCB, No. 101, Lane _ 169, Kangning St., New Taipei City, 221 (TW). LIAO, _ Chu-bin; c/o DCB, No. 101, Lane 169, Kangning St New , Taipei City, 221 (TW). CHEN, Hung-Kai; c/o DCB, No. = 101, Lane 169, Kangning St., New Taipei City, 221 (TW). HO, Chen-Hsuan; c/o DCB, No. 101, Lane 169, Kangning = St., New Taipei City, 221 (TW). HUANG, Hung-Jyun; c/ o DCB, No. 101, Lane 169, Kangning St., New Taipei City, 221 (TW). CHIOU, Shian-Yi; c/o DCB, No. 101, Lane — = 169, Kangning St., New Taipei City, 221 (TW). (74) Agent: LIANG, T., Chyau; Liang Legal Group, PLLC, 6020 Annapolis Street, Houston, TX 77005 (US). —— Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = (81) = = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, — DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = = OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = — SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — 1-1 GC (54) Title: QUINOXALINE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS 71' M (57) : A compound, capable of inhibiting kinases, for the treat- 1-1 R 2 ments of diseases or disorders mediated by such kinases, has a structure IN R 1 X R14] of formula (I) or a stereoisomer, a tautomer, a pharmaceutically accept- = --.... (I) able salt thereof. The compound can be used in the treatments of diseases 1 0 1-1 N U Z G or conditions mediated by CSF-IR, c-KIT, FLT3, or PDGFR kinases. = ei Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases. O

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式